A single determination of eGFR associates with subsequent mortality risk. Prior decline in eGFR indicates loss of kidney function, but the relationship to mortality risk is uncertain. We conducted an individuallevel metaanalysis of the risk of mortality associated with antecedent eGFR slope, adjusting for established risk factors, including last eGFR, among 1.2 million subjects from 12 CKD and 22 other cohorts within the CKD Prognosis Consortium. Over a 3year antecedent period, 12% of participants in the CKD cohorts and 11% in the other cohorts had an eGFR slope <−5 ml/min per 1.73 m per year, whereas 7% and 4% had a slope >5 ml/min per 1.73 m per year, respectively. Compared with a slope of 0 ml/min per 1.73 m per year, a slope of −6 ml/min per 1.73 m per year associated with adjusted hazard ratios for allcause mortality of 1.25 (95% confidence interval [95% CI], 1.09 to 1.44) among CKD cohorts and 1.15 (95% CI, 1.01 to 1.31) among other cohorts during a followup of 3.2 years. A slope of +6 ml/min per 1.73 m per year also associated with higher all-cause mortality risk, with adjusted hazard ratios of 1.58 (95% CI, 1.29 to 1.95) among CKD cohorts and 1.43 (95% CI, 1.11 to 1.84) among other cohorts. Results were similar for cardiovascular and noncardiovascular causes of death and stronger for longer antecedent periods (3 versus <3 years). We conclude that prior decline or rise in eGFR associates with an increased risk of mortality, independent of current eGFR.
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Keywords: chronic kidney disease, glomerular filtration rate, mortality, epidemiology, outcomes CKD affects 10%-16% of the global population. Numerous studies have reported the significant association of low eGFR at a single time point with mortality, a more frequent occurrence than ESRD, even among patients with late stages of CKD. Recently, there has been great interest in whether a decline in eGFR adds information to mortality risk assessment beyond eGFR at a single time point. Clinicians are often faced with a situation in which current eGFR is known along with its past trajectory. Thus, a clinically relevant question is whether past trajectory of eGFR can provide additional information beyond current eGFR.
A surprising finding in previous studies was that an increase in eGFR was associated with an increased risk of mortality. Whether these observations are generalizable is uncertain, because they were on the basis of data from single centers and/or cohorts with mean baseline eGFR values of ≥50 ml/min per 1.73 m .
Improvement in eGFR in a CKD population might show different associations with mortality than that in a general population cohort. In addition, the Ushaped association might be driven by confounding factors, such as weight loss or heart failure. Thus, a comprehensive investigation about eGFR increase and mortality risk is warranted.
The objective of the study was to use metaanalysis to address two clinically relevant questions: given patients presenting with a particular eGFR, does the prior eGFR trajectory provide additional prognostic information with respect to mortality risk beyond the present eGFR per se, and if so, what is the shape of this relationship?
Results

Associations with eGFR Slope
Over a 3year antecedent period, median (interquartile range [IQR] ) numbers of creatinine measurements were 7 (IQR, 7-7) in the CKD and 5 (IQR, [4] [5] in the other (general population/high cardiovascular risk) cohorts; 12% of participants in the CKD and 11% of participants in the other cohorts had an eGFR slope <−5 ml/min per 1.73 m per year, whereas 7% and 4% experienced an eGFR slope >+5 ml/min per 1.73 m per year during the antecedent period, respectively. There were no consistent differences in the age or sex distribution between subjects with antecedent slopes of <−5, ≥−5 to ≤+5, and >+5 ml/min per 1.73 m year; however, black subjects tended to be in the <−5 ml/min per 1.73 m category (Supplemental Table 1,  Table 1 ). Subjects with annual slopes <−5 ml/min per 1.73 m per year had a higher prevalence of elevated albuminuria, were more often diabetic, and were more likely to have a history of cardiovascular disease (CVD) compared with subjects in the stable or increasing eGFR slope categories (Supplemental Table 2 ).
After adjustment, lower current eGFR, younger age, black race, higher total cholesterol, the presence of diabetes, and the presence of albuminuria (severely increased only in CKD cohorts; moderately increased and severely increased in the other cohorts) were associated with antecedent slope <−5 ml/min per 1.73 m per year (Supplemental Table 3 included higher current (last) eGFR, women, history of CVD, and the presence of albuminuria (severely increased only in CKD cohorts; moderately increased and severely increased in the other cohorts).
AllCause Mortality
Among cohorts with 3year antecedent data, 102,477 of 1,277,217 subjects died (8%) over a mean follow up time of 3.2 years (Supplemental Table 4 Table 5 ).
Risk of AllCause Mortality Associated with a Decline in eGFR
Compared with subjects with no change in eGFR over the antecedent 3year period, a slope of −6 ml/min per 1.73 m per year was associated with hazard ratios (HRs) for allcause mortality (ACM) of 1. Table 6 ). The risk of ACM associated with an annual eGFR decline was attenuated with shorter antecedent periods (corresponding to smaller absolute eGFR declines) (Supplemental Figure 1 ).
For both CKD and other cohorts, there was no statistically significant interaction of current eGFR and antecedent eGFR slope with ACM (P for interaction =0.17 and 0.19, respectively) ( Figure 2 ). Higher current albuminuria was associated with higher ACM risk. Among albuminuria strata, the association between antecedent eGFR slope and ACM mortality overlapped only in the extremes of the eGFR slope distribution in the CKD cohorts and was roughly parallel by level of albuminuria in the other cohorts, suggesting a similar absence of interaction between current albuminuria and antecedent eGFR decline (P for interaction =0. Figure 2 ).
The risk associated with an eGFR slope of −6 ml/min/ per 1.73 m per year over the 3year antecedent period showed heterogeneity ( Figure 3 ). Among CKD cohorts, metaregression suggested that differences in followup time (with higher HRs associated with shorter followup) and median age (with higher HRs associated with older age) may have accounted for some heterogeneity (Supplemental Figure 3) , whereas for the other cohorts, heterogeneity was not explained by metaregression (Supplemental Figure 4) .
For the CKD cohorts, absolute risk of ACM was higher with greater antecedent decline in eGFR, but current eGFR was relatively more important in determining the absolute mortality risk. Absolute risk of ACM in the other cohorts was low (Supplemental Table 7 ).
Risk of ACM Associated with an Increase in eGFR
ACM risk associations of antecedent eGFR increase were at least as strong as those for eGFR decline and mortality ( Figure 1 ). Compared with subjects with no change in eGFR over the antecedent 3year period, a slope of +6 ml/min per 1.73 m per year was associated with HRs for ACM of 1.58 (95% CI, 1.29 to 1.95) for the CKD cohorts and 1.43 (95% CI, 1.11 to 1.84) among members of the other cohorts ( Figure 1 , Supplemental Table 6 ). The risk associated with an eGFR slope of +6 ml/min per 1.73 m per year over the 3year antecedent period showed heterogeneity across both CKD and other cohorts ( Figure 4 ). The absolute risk of ACM was higher among members of the CKD versus the other cohorts, with current eGFR being a more important risk factor than antecedent slope (Supplemental Table 7 ).
The association of eGFR increase and mortality remained significant in all sensitivity analyses. Participants with positive eGFR slopes in the other cohorts had a trend toward higher risk of both cardiovascular and noncardiovascular mortality, although risk associations were attenuated (Table 2) . Similarly, the increased risk of ACM associated with a positive eGFR slope in the antecedent period persisted when we included a measure, the root mean squared error (RMSE), of each individual's variation around the eGFR slope line as a covariate in the Cox model (Supplemental Figure 5 ) or when the model was stratified by RMSE (Supplemental Figure 6 ). Although weight loss of >2.0 kg was associated with increased odds of eGFR rise, excluding subjects who lost >2.0 kg during the antecedent 3 years did not alter the Ushaped relationship between antecedent eGFR slope and ACM (Supplemental Figure 7 ). Excluding patients with diabetes and either adjusting for or stratifying by use of reninangiotensin systeminhibiting medications in the antecedent period made no meaningful difference in the risk associations (Supplemental Figures 8-10 ).
Analyses using percentage change of eGFR rather than slope are shown in Supplemental Figure 11 . Because a given absolute change in eGFR represents a higher percentage change for persons with lower current eGFR values and because the CKD cohorts had, in general, lower current eGFR, the distribution of percentage decline is shifted to the left for the CKD relative to the other cohorts, such that a greater number of persons in the CKD cohorts experienced a ≥30% reduction in eGFR over 3 years. Nonetheless, risk associations were similar to slightly stronger when prior eGFR trajectory was assessed as a percentage change rather than slope (Supplemental Figure 11 ). Compared with an adjusted Cox model without eGFR slope, the addition of the latter resulted in a marginal improvement in the discrimination with respect to ACM: pooled estimates for the resulting change of c statistics were 0.003 (95% CI, −0.000 to 0.007) and 0.002 (95% CI, 0.001 to 0.004) for the CKD and other cohorts, respectively (Supplemental Table 8 ).
Discussion
In this analysis of >1.2 million subjects and >100,000 deaths, we found that antecedent eGFR slope over a 3year period, whether positive or negative, exhibited a statistically significant association with ACM, cardiovascular mortality, and noncardiovascular mortality. These associations were observed even after adjustment for current eGFR (last eGFR in the antecedent period), suggesting that there is modest incremental information in the prior eGFR trajectory beyond eGFR measured at a single time point. In general, large changes in eGFR were unusual (11% for <−5 ml/min per 1.73 m per year and 5% for >5 ml/min per 1.73 m per year), but associated with the highest risk of mortality, whereas lesser changes were more common, but associated with smaller risks. Antecedent improvement in eGFR was associated with a mortality risk similar in magnitude to antecedent decline. This association persisted in numerous sensitivity analyses, suggesting that rapid change in creatininebased eGFR-whether for the worse or the better-may be a poor prognostic sign. The relationship between antecedent eGFR slope and ACM was apparent across the entire spectrum of current eGFR, but at least within CKD cohorts, current eGFR had a much greater effect on absolute mortality risk than did prior trajectory.
Previous studies have shown that low eGFR measured at a single time point is an important risk factor for ACM. We sought to evaluate whether prior change in eGFR contributes independently to ACM prognosis in the clinical setting, where last eGFR value is known. Previous studies have investigated this association from a clinical trial perspective, adjusting for the first eGFR. The latter is relevant for the situation where two subjects begin a clinical trial at the same eGFR value, but one maintains a stable eGFR, whereas the other subject's eGFR either falls or rises. In contrast, adjustment for last eGFR during the antecedent period, as per this analysis, replicates the clinical scenario, whereby ACM risk is compared between two patients who present with the same eGFR value, but one has had a stable eGFR, and the other has either fallen or risen to that value. Similar to previous work, in which adjustments were made for either the first or last eGFR in the antecedent period, we found a Ushaped relationship between eGFR slope and subsequent ACM risk.
Direct, quantitative comparison between the results of these investigations and our own investigations are hampered by different indices of renal function change, different antecedent periods, and the use of rates, in some studies, rather than HRs to quantify mortality risk. However, Turin et al. found adjusted HRs for ACM of 1.14 and 1.68 for 4ml/min per 1.73 m per year declining and increasing slopes, respectively, compared with subjects with a stable eGFR value in a Canadian population-based study. These values are qualitatively similar to those for the other (general population and high risk) cohorts in this analysis. The small quantitative difference may be caused by differences in the set of adjustment factors used in the two studies. Note that data from the latter cohort were included in this analysis.
Several mechanisms may underlie the association of antecedent change in eGFR and mortality. In principle, change in creatininebased eGFR may reflect either change in true GFR-caused by progression or remission of CKD or onset or recovery from acute kidney disease-or change in nonfiltration determinants of serum creatinine, such as muscle wasting or malnutrition. A steeper antecedent eGFR decline has been traditionally held to signify past decline in true GFR. Thus, in this study, the true GFR for individuals with a steeper eGFR decline in the antecedent period may have continued to decline in the followup period below the last or current true GFR, and lower true GFR per se is expected to be associated with mortality. Alternatively, an antecedent decline in true GFR may simply reflect a more severe comorbidity profile. For example, although we adjusted for diabetes and our findings were qualitatively similar after excluding subjects with diabetes, we did not adjust for severity of diabetes, a key determinant of both true GFR decline and mortality risk.
Similarly, episodes of acute coronary syndrome or congestive heart failure may increase the risk of death and also, cause true GFR decline. However, we observed similar associations of antecedent eGFR decline with nonCVD mortality as we did with CVD mortality (albeit in the limited cohorts with these data). Previous investigations have suggested that variability in the eGFR itself may be associated with higher ACM risk. However, in this study, with individual residual eGFR variation expressed as the RMSE, we found little attenuation of the effect of decreasing (or increasing) eGFR slope on ACM.
The association between increasing eGFR and mortality is less intuitive. Rather than indicating improving true GFR, a rising eGFR may be an indicator of declining muscle mass or malnutrition, with the latter being responsible for the increase in ACM risk. However, exclusion of subjects who lost weight attenuated the risk of ACM on both ends of the eGFR slope spectrum but did not eliminate the U shape. Furthermore, a previous study reported an association between higher ACM risk and positive eGFR slope using cystatin C as a filtration marker, although cystatin C levels are less affected by muscle mass than creatinine, suggesting that a rising eGFR may reflect a rising true GFR. A rising prior true GFR may be caused by recovery from acute kidney disease associated with an acute illness, and it was the latter that was responsible for the observed increase in ACM risk rather than the rising true GFR per se. Finally, a rising true GFR could be seen with hyperfiltration in remnant nephrons, which could be associated with subsequent kidney disease progression, but it is not generally hypothesized to be associated with mortality. Because singlenephron GFR cannot be measured in humans, this mechanism remains speculative.
The strengths of this analysis include its large sample size with geographically diverse general population, high CVD risk, and CKD cohorts with current eGFR values that spanned a wide spectrum. We used an index of eGFR change that is commonly used in the clinical setting, the annualized eGFR slope, and in sensitivity analyses, the percentage change in eGFR. We estimated ACM risks with a uniform metaanalytic approach using individuallevel data across collaborating cohorts. Our study also has limitations. The general/highrisk cohorts enrolled generally younger persons and were less representative with respect to elderly individuals than the CKD cohorts. As in all observational studies, residual confounding is possible, and we captured only certain comorbidities. Laboratory assays were not uniform, but where possible, serum creatinine measures were calibrated to isotope dilution mass spectrometry standards. Variation in cohort study design as well as study population might introduce heterogeneity, but the relative consistency across cohorts, despite these variations, points toward the robustness of our findings. Finally, P values close to the nominal level of significance may be prone to type 1 error given the number of statistical tests involved in our analyses. In conclusion, compared with patients with a stable eGFR, those with either an antecedent rise or fall in values were at increased risk of subsequent mortality. Prior change of eGFR over 3 years contributed additional information regarding mortality risk beyond the current eGFR itself. However, these incremental risks were clinically meaningful only for large eGFR changes, which were uncommon. Future research could focus on new filtration markers or direct GFR measurement to help to elucidate the nature of the relationship between rising eGFR and mortality risk.
Concise Methods
Cohort Selection Criteria
The Chronic Kidney Disease Progression Consortium includes cohorts in which the presence of CKD was required for cohort entry and those in which entry was determined by factors other than CKD (general population and high-CVD risk cohorts; i.e., other cohorts). This study involved 35 cohorts (13 CKD and 22 other) and included subjects ≥18 years of age who had repeated serum creatinine measurements during antecedent intervals from 1 to 3 years in duration. For the main analysis, we included 34 cohorts (12 CKD and 22 other) that could provide data for a 3year antecedent period. This study was approved by the Institutional Review Board at the Johns Hopkins Bloomberg School of Public Health.
Antecedent Change in eGFR
eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration 2009 creatinine equation. In cohorts without standardization of creatinine measurement to isotope dilution mass spectrometry, reported creatinine levels were multiplied by 0.95. For each participant, annualized eGFR slope (milliliters per minute per 1.73 m per year) was derived from ordinary least squares regression using all eGFR measurements available during the antecedent period. This study focuses on the population with available data in the 3year antecedent interval (results for 1 and 2year periods are presented in Supplemental Material). Rapidly declining, stable, and rapidly increasing eGFR slope were defined as antecedent slopes of <−5, −5 to +5, and >+5 ml/min per 1.73 m per year, respectively.
Assessment of Baseline Covariates
Within the antecedent period, we considered the last eGFR as the current eGFR. The last eGFR measurement was taken at 3±0.5 years (i.e., between 2.5 and 3.5 years after the first available eGFR). All covariates were assessed within 1 year before the last eGFR measurement during the antecedent period. Diabetes was defined as fasting glucose ≥7.0 mmol/L (126 mg/dl), nonfasting glucose ≥11.1 mmol/L (200 mg/dl), hemoglobin A1c ≥6.5%, use of antiglycemic drugs, or selfreported diabetes. Prior myocardial infarction, coronary revascularization, heart failure, or stroke was considered as a history of CVD. Albuminuria was categorized as none, moderately increased, or severely increased.
Assessment of Outcomes
The primary study outcome was ACM occurring subsequent to the antecedent time period, with time at risk starting at the last measurement of eGFR (current). In Supplemental Material, we analyzed cardiovascular and noncardiovascular mortality when data were available (i.e., for 14 of the other cohorts).
Statistical Analyses
We performed two-stage metaanalyses, whereby each cohort was first analyzed separately and then pooled using random effect models (Supplemental Appendix 1). We imputed missing values of covariates (except eGFR) using cohort-specific mean values. Covariates that were completely missing for a particular cohort were excluded from the regression model for that cohort. We assessed heterogeneity with the I statistic and random effects meta-regression analyses. Because the distributions of antecedent eGFR slope -, , may be different among other and CKD cohorts, we a priori designed the metaanalyses to be stratified by cohort type.
Within each cohort, we estimated the adjusted HRs of ACM according to GFR slope with piecewise linear splines (knots at −10, −5, −3, −1, +1, and +3 ml/min per 1.73 m per year). Cox models were adjusted for age, sex, race (black versus nonblack), systolic BP, total cholesterol, diabetes, history of CVD, and current eGFR. Adjustment for albuminuria was done only in secondary analyses, because albuminuria was not measured in conjunction with the last available eGFR in several cohorts. Forest plots of HR estimates at eGFR slopes of −6 and +6 ml/min per 1.73 m per year were constructed (chosen as representative values within the rapid declining and rising eGFR slope categories, respectively). Differential effects of current eGFR and albuminuria on the relationship between change in eGFR and ACM were evaluated with interaction terms. We computed the basecase cumulative hazard of ACM at 1, 3, 5, and 10 years after baseline (Supplemental Appendix 2). Absolute risk was calculated by multiplying the meta-analyzed adjusted HRs for eGFR slopes of −6, −4, −2, 0, +2, +4, and +6 ml/min per 1.73 m per year by the pooled basecase cumulative hazard. The improvement in discrimination with respect to ACM was assessed with the difference in c statistics for an adjusted model with and without eGFR slope as a covariate.
Because of an observed risk increase with antecedent increase in eGFR, we conducted several sensitivity analyses. First, we evaluated the associations of antecedent eGFR slope with cardiovascular (death caused by myocardial infarction, heart failure, stroke, or sudden cardiac death) and noncardiovascular (all other etiologies) mortality. Second, we assessed the effect of individual residual eGFR variability. We used the RMSE as an indicator of the variation of an individual's eGFR values around his or her ordinary least squares regression line. The RMSE was included as a covariate and then, a stratifying variable (categorized as <5, 5-10, and >10). Third, to explore whether increasing eGFR reflected weight loss, we excluded subjects with antecedent weight loss >2 kg over the 3year period. Fourth, to evaluate whether the U-shaped risk relationship might represent diabetes-associated glomerular hyperfiltration, we repeated analyses excluding persons with diabetes mellitus. Fifth, analyses were repeated according to whether individuals had ever been exposed to reninangiotensinsystem blocking medications in the antecedent interval as a covariate in the Cox model and then, a stratifying variable. Analyses were performed using Stata/SE 13 software (StataCorp., College Station, TX; www.stata.com). P values <0.05 were considered statistically significant.
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